Latest news with #PaloAlto
Yahoo
9 hours ago
- Business
- Yahoo
In Largest Molecular Residual Disease (MRD) Study in Colon Cancer, Guardant Reveal Testing Prior to Chemotherapy Provides Robust Stratification for Risk of Disease Recurrence and Survival to Enable Timely Treatment Decisions
Data support routine use of circulating tumor DNA testing in management of stage III colon cancer patients Tumor fraction analysis provides further insights for patient management in patients with ctDNA detected PALO ALTO, Calif., May 31, 2025--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and its research collaborators today presented results of the largest study to date evaluating circulating tumor DNA (ctDNA) in colon cancer prior to chemotherapy, demonstrating the ability of the Guardant Reveal™ test to stratify the risk of disease recurrence and overall survival, and thus inform treatment decisions after surgery. Data from the phase III trial of FOLFOX-based adjuvant chemotherapy (NCCTG N0147) involving over 2,000 patients with stage III colon cancer with median follow-up of 6.1 years were presented at the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting. Results demonstrated that circulating tumor DNA detected in the bloodstream after cancer surgery and prior to the start of adjuvant therapy, using the Guardant Reveal test, is a strong predictor of the risk of disease recurrence and poorer survival, and suggest the potential for ctDNA testing to improve decision-making at a critical time point for post-operative chemotherapy. Specifically: Among patients with post-surgical ctDNA detected, 62.6% had the cancer return within 3 years, despite having had adjuvant chemotherapy, while only 15.4% of patients with undetectable ctDNA recurred in the same period. The level of ctDNA, or tumor fraction, showed promise in identifying individuals who are less likely to clear residual disease with adjuvant treatment. "Thirty percent of patients with stage III colon cancer will relapse after surgery, despite having standard adjuvant chemotherapy," said Frank Sinicrope, MD, professor of oncology and medicine at Mayo Clinic and principal investigator for the study. "In this study, we demonstrate that analysis of postsurgical ctDNA can improve the prediction of disease recurrence over standard staging criteria, which may help guide patient management and follow-up. These data further support the routine use of ctDNA in management of stage III colon cancer patients." "With the Guardant Reveal test, a simple blood draw can be used to identify colorectal cancer patients who have molecular residual disease and are most likely to benefit from adjuvant therapy," said Helmy Eltoukhy, Guardant Health chairman and co-CEO. "This large study confirms the test's ability to identify high risk of cancer returning and support oncologists in making more informed therapeutic decisions to help improve patient outcomes." The full abstract for the presentation can be found on the ASCO website. About Guardant Reveal Guardant Reveal, which runs on the Guardant Infinity™ smart liquid biopsy platform, is a blood test that uses epigenomic (methylation) analysis to detect circulating tumor DNA, a marker of minimal residual disease, to predict cancer recurrence, helping to guide clinical decisions after surgery or chemotherapy. The test is covered by Medicare for patients with colorectal cancer in the early post-surgical setting and for surveillance testing to monitor for disease recurrence after curative intent treatment. About Molecular Residual Disease Molecular residual disease refers to a subclinical measure of cancer burden that remains during and following treatment. A patient's MRD status is a reliable indicator of clinical outcome and response to therapy and can be used for risk stratification and to guide treatment options when used in conjunction with other clinical data. About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit and follow the company on LinkedIn, X (Twitter) and Facebook. Forward-Looking Statements This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health's liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health's financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2024, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health's views as of any date subsequent to the date of this press release. View source version on Contacts Investor Contact: Zarak Khurshidinvestors@ Media Contact: Michael Weistpress@ +1 317-371-0035
Globe and Mail
a day ago
- Business
- Globe and Mail
Broadcom Just Got a New Street-High Price Target. Should You Buy AVGO Stock Now?
Broadcom (AVGO) recently received a vote of confidence from Redburn Atlantic, which initiated coverage of the stock with a 'Buy' rating. The firm pointed to the company's strong position in application-specific integrated circuits (ASICs) as a key driver of long-term growth. Analyst Mike Harrison set a price target of $301, a new Street high. The bullish call adds to recent optimism around Broadcom, with recent price target hikes from Melius Research and Mizuho. Broadcom's fiscal first-quarter earnings showed a 25% jump in revenue year over year, with AI-related sales playing a growing role. As investor interest in AI and cloud infrastructure grows, analysts appear increasingly confident in Broadcom's ability to deliver sustained performance. About Broadcom Stock Broadcom (AVGO), headquartered in Palo Alto, California, is renowned for its diverse portfolio of semiconductor products, coupled with its infrastructure software solutions. Valued at $1,1 trillion, the company's shares have soared by 71% over the past 52 weeks, showcasing its resilience. Broadcom Surpasses on Fiscal Q1 Earnings On March 6, Broadcom released its fiscal Q1 2025 earnings, surpassing Wall Street's expectations. The company reported revenue of $14.9 billion, comfortably ahead of the $14.6 billion forecast and marking a 25% year-over-year jump. The sharp uptick was powered by artificial intelligence and infrastructure software, each clocking in growth well above 40%. AI revenue soared by 77%, reaching $4.1 billion. The infrastructure segment saw a 47% rise in revenue, reaching $6.7 billion during the quarter. The company's adjusted EBITDA climbed 40.9%, totaling $10.1 billion. Non-GAAP EPS surged by 45.5%, hitting $1.60, easily surpassing the forecast $1.51. Adding to the positive momentum, Broadcom's free cash flow increased by 28.1% to $6 billion. As a testament to their confidence in future growth, management also announced a $10 billion stock buyback program in early April, set to run through the end of the year. CEO Hock Tan has emphasized that this move underscores the board's trust in Broadcom's diversified product lineup. Looking ahead, management has projected fiscal Q2 2025 revenue to reach $14.9 billion, reflecting a 19% increase from the previous year. Meanwhile, analysts tracking Broadcom forecast Q2 EPS to grow 54% year-over-year to $1.34, and fiscal 2025 EPS to rise 53.9% from the prior to $5.71. What Do Analysts Expect for Broadcom Stock? Wall Street's sentiment toward AVGO is nothing short of bullish. Analysts are clearly betting on the company's momentum to continue, especially with tailwinds like AI and infrastructure software business growth adding fuel to the fire. The company will release its fiscal Q2 earings on June 5, which should also grab investor attention. The stock currently enjoys a 'Strong Buy' consensus, a reflection of widespread confidence in its performance trajectory. Among 33 analysts, 29 advocate a 'Strong Buy,' one has a 'Moderate Buy,' and three sit on the fence with a 'Hold.' The average price target of $243.86 represents minimal upside from current prices, while the Street-high price target of $301 suggests shares could gain 24% from here.
Globe and Mail
2 days ago
- Business
- Globe and Mail
Broadcom's Private Cloud Outlook 2025 Report Reveals Definitive Cloud Reset
Private cloud now rated as a strategic equal to public cloud, driven by cost predictability, GenAI requirements, and trust in delivering on security and compliance needs 53% surveyed say private cloud is their top priority for deploying new workloads over the next three years 84% use private cloud for both traditional enterprise apps and modern, cloud-native workloads PALO ALTO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Private clouds are no longer playing catch-up, and public clouds are no longer the default as organizations recalibrate their cloud strategies. This 'cloud reset' was the key takeaway from the Private Cloud Outlook 2025 report, an in-depth global survey of 1,800 senior IT leaders conducted by Illuminas, in partnership with Broadcom Inc. (NASDAQ: AVGO). More than half (53%) of survey respondents say private cloud is their top priority for deploying new workloads over the next three years, while 69% are considering workload repatriation from public to private cloud, with one-third having already done so. Private cloud is also now a strategic equal for AI and cloud-native apps, with 66% preferring to run container and Kubernetes-based applications on private cloud or a mix of public and private, while 55% prefer private cloud for AI model training, tuning and inference. 'This report makes it clear: private cloud is a strategic platform for IT modernization,' said Prashanth Shenoy, vice president of product marketing, VMware Cloud Foundation Division (VCF) at Broadcom. 'Customers are intentionally architecting for flexibility, placing workloads in environments that offer the best balance of performance, control, and cost efficiency. The cloud reset presents an opportunity to create a more effective, secure and cost-efficient IT environment. Organizations that strategically adopt a modern private cloud can better support secure GenAI innovation, improve fiscal visibility, and accelerate workload repatriation.' Security, GenAI, and Cost Predictability Accelerate the Shift to Private Cloud As IT leaders modernize their infrastructure, they are increasingly turning to private cloud to meet a range of critical needs, from securing sensitive data to managing unpredictable GenAI workloads to improving financial visibility. Security and compliance 92% trust private cloud for security and compliance needs. 66% are "very" or "extremely" concerned about public cloud compliance, and security is cited as the leading driver for workload repatriation from public cloud. Generative AI requirements Data privacy and security concerns (49%) top the list of GenAI adoption challenges. Organizations are choosing private cloud environments for AI workloads at nearly the same rate as public cloud (55% vs. 56%). Cost predictability and reduction 90% value private cloud's financial visibility and predictability. 94% report at least some level of waste on public cloud spend. 49% believe more than 25% of their public cloud spend is wasted, creating significant optimization opportunities. Accelerating the Private Cloud Momentum Real-world public cloud experiences, the rapid rise of GenAI workloads, and increasing demands for security, compliance, and cost predictability are driving this strategic cloud realignment. To fully capitalize on private cloud advantages, organizations must address two key challenges: overcoming siloed IT teams and a perpetuating skills gap. Respondents identified siloed IT teams present the greatest challenge to private cloud adoption (33%), and 30% cite a lack of in-house skills/expertise as a barrier to private cloud adoption. Organizations that transition from technology silos to platform teams can focus on upskilling staff to permanently close the skills gap and reduce reliance on professional services. The report found that 81% are now structuring their technical organizations around a platform team rather than technology silos. View the full survey and learn about additional report findings here. Survey Methodology and Definitions The Private Cloud Outlook 2025 is based on a global survey conducted by market research firm Illuminas on behalf of Broadcom. The survey was fielded from March 6 to April 4, 2025, and included 1,800 senior IT decision-makers across small, medium-sized, and large enterprises in North America, Europe, and Asia Pacific. Respondents represented sectors such as financial services, government, healthcare, insurance, and pharmaceuticals. The study presented the following descriptions of cloud for reference to participants, aligned with Broadcom's definitions as well as with NIST standards: Cloud computing is a model for enabling ubiquitous, convenient, on-demand network access to a shared pool of configurable computing resources (e.g., networks, servers, storage, applications, and services) that can be rapidly provisioned and released with minimal management effort or service provider interaction. Private cloud is a dedicated cloud infrastructure provisioned for the exclusive use of a single organization. This infrastructure may be managed by the organization itself or by a third party and can be located on-premises or at a co-location facility. Public cloud is shared cloud infrastructure run by a third-party service provider. It is accessible to anyone, including the general public, and, for the purposes of this survey, does not include SaaS such as Microsoft 365, Workday, or ServiceNow. About Broadcom Broadcom Inc. (NASDAQ: AVGO) is a global technology leader that designs, develops, and supplies a broad range of semiconductor, enterprise software and security solutions. Broadcom's category-leading product portfolio serves critical markets including cloud, data center, networking, broadband, wireless, storage, industrial, and enterprise software. Our solutions include service provider and enterprise networking and storage, mobile device and broadband connectivity, mainframe, cybersecurity, and private and hybrid cloud infrastructure. Broadcom is a Delaware corporation headquartered in Palo Alto, CA. For more information, go to Broadcom, the pulse logo, and Connecting Everything are among the trademarks of Broadcom. The term "Broadcom" refers to Broadcom Inc., and/or its subsidiaries. Other trademarks are the property of their respective owners. Media Contact:
Washington Post
3 days ago
- Business
- Washington Post
HP: Fiscal Q2 Earnings Snapshot
PALO ALTO, Calif. — PALO ALTO, Calif. — HP Inc. (HPQ) on Wednesday reported fiscal second-quarter profit of $406 million. The Palo Alto, California-based company said it had net income of 42 cents per share. Earnings, adjusted for one-time gains and costs, came to 71 cents per share. The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of 80 cents per share.
CNBC
3 days ago
- Business
- CNBC
Trade Tracker: Malcolm Ethridge sells Palo Alto
Malcolm Ethridge, Managing Partner at Capital Area Planning Group, joins CNBC's Halftime Report to explain why he's selling Palo Alto.
